CMRA vs. INM, DRMA, PBLA, QLGN, GLMD, LSDI, GRI, BPTH, CMND, and HSTO
Should you be buying Comera Life Sciences stock or one of its competitors? The main competitors of Comera Life Sciences include InMed Pharmaceuticals (INM), Dermata Therapeutics (DRMA), Panbela Therapeutics (PBLA), Qualigen Therapeutics (QLGN), Galmed Pharmaceuticals (GLMD), Lucy Scientific Discovery (LSDI), GRI Bio (GRI), Bio-Path (BPTH), Clearmind Medicine (CMND), and Histogen (HSTO). These companies are all part of the "pharmaceutical preparations" industry.
InMed Pharmaceuticals (NASDAQ:INM) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation, community ranking and media sentiment.
InMed Pharmaceuticals has a net margin of -115.76% compared to InMed Pharmaceuticals' net margin of -904.00%. InMed Pharmaceuticals' return on equity of 0.00% beat Comera Life Sciences' return on equity.
In the previous week, InMed Pharmaceuticals had 1 more articles in the media than Comera Life Sciences. MarketBeat recorded 1 mentions for InMed Pharmaceuticals and 0 mentions for Comera Life Sciences. Comera Life Sciences' average media sentiment score of 0.36 beat InMed Pharmaceuticals' score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the media.
20.1% of InMed Pharmaceuticals shares are held by institutional investors. 1.4% of InMed Pharmaceuticals shares are held by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
InMed Pharmaceuticals received 8 more outperform votes than Comera Life Sciences when rated by MarketBeat users.
InMed Pharmaceuticals has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500. Comparatively, Comera Life Sciences has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500.
InMed Pharmaceuticals has higher revenue and earnings than Comera Life Sciences.
Summary
InMed Pharmaceuticals beats Comera Life Sciences on 8 of the 12 factors compared between the two stocks.
Get Comera Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Comera Life Sciences Competitors List
Related Companies and Tools
